Novartis AG (CH:NOVN)
:NOVN
Want to see CH:NOVN full AI Analyst Report?
NOVN Stock Chart & Stats
CHF118.82
-CHF1.10(-1.10%)
At close: 4:00 PM EST
CHF118.82
-CHF1.10(-1.10%)
Day’s Range― - ―
52-Week RangeCHF91.20 - CHF131.00
Previous CloseN/A
Volume858.75K
Average Volume (3M)2.71M
Market Cap
CHF215.49B
Enterprise ValueCHF329.27B
Total Cash (Recent Filing)CHF7.00B
Total Debt (Recent Filing)CHF47.14B
Price to Earnings (P/E)20.8
Beta1.00
Next Earnings
Jul 21, 2026EPS Estimate
1.73Next Dividend Ex-DateN/A
Dividend Yield3.18%
Share Statistics
EPS (TTM)6.98
Shares Outstanding2,034,819,500
10 Day Avg. Volume2,438,245
30 Day Avg. Volume2,709,021
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)5.81
Price to Sales (P/S)4.69
P/FCF Ratio14.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF125.70Price Target Upside5.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)8.71
Revenue Forecast (FY)CHF56.72B
Bulls Say, Bears Say
Bulls Say
High Profitability & MarginsSustained high gross and operating margins indicate durable pricing power and efficient cost structure across multiple therapeutic areas. High margins support consistent R&D funding, dividend capacity and resiliency to reimbursement pressures, underpinning long-term profitability.
Substantial Cash GenerationLarge absolute free cash flow and high cash conversion provide strategic optionality for capex, manufacturing expansion, bolt-on M&A and shareholder returns. Robust cash generation is a structural strength that cushions the business through cycle and funds pipeline commercialization.
Meaningful U.S. Manufacturing ExpansionA multi‑billion dollar build‑out and new RLT/API facilities onshore improve supply resilience, shorten time‑to‑patient and scale capacity for radioligand and RNA therapies. This structural investment strengthens commercialization capabilities and competitive positioning in key markets.
Bears Say
Rising LeverageHigher leverage reduces financial flexibility and raises interest expense sensitivity, constraining capital allocation choices. With equity declining versus prior years, the balance sheet now has a smaller cushion, increasing risk if cash flows weaken or if financing costs rise.
Weakening FCF GrowthA steep drop in free cash flow growth signals recent operational or working‑capital headwinds that erode the pace of cash available for reinvestment and returns. Persisting negative FCF growth would limit runway for expansion and make funding choices more trade‑off driven.
Modest Revenue DeclineA visible decline in trailing revenues points to near‑term demand, pricing or lifecycle pressures in some franchises. If sustained, revenue erosion can force higher reliance on margin improvements or pipeline launches to replace lost sales, raising execution risk over the medium term.
NOVN FAQ
What was Novartis AG’s price range in the past 12 months?
Novartis AG lowest stock price was CHF91.20 and its highest was CHF131.00 in the past 12 months.
What is Novartis AG’s market cap?
Novartis AG’s market cap is CHF215.49B.
When is Novartis AG’s upcoming earnings report date?
Novartis AG’s upcoming earnings report date is Jul 21, 2026 which is in 32 days.
How were Novartis AG’s earnings last quarter?
Novartis AG released its earnings results on Apr 28, 2026. The company reported CHF1.589 earnings per share for the quarter, missing the consensus estimate of CHF1.68 by -CHF0.091.
Is Novartis AG overvalued?
According to Wall Street analysts Novartis AG’s price is currently Undervalued.
Does Novartis AG pay dividends?
Novartis AG pays a Annually dividend of CHF3.7 which represents an annual dividend yield of 3.18%. See more information on Novartis AG dividends here
What is Novartis AG’s EPS estimate?
Novartis AG’s EPS estimate is 1.73.
How many shares outstanding does Novartis AG have?
Novartis AG has 2,034,819,500 shares outstanding.
What happened to Novartis AG’s price movement after its last earnings report?
Novartis AG reported an EPS of CHF1.589 in its last earnings report, missing expectations of CHF1.68. Following the earnings report the stock price went up 0.561%.
Which hedge fund is a major shareholder of Novartis AG?
Currently, no hedge funds are holding shares in CH:NOVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novartis AG
Novartis AG is a global pharmaceutical company dedicated to the discovery, development, production, and commercialization of a broad spectrum of healthcare solutions. Its business operations are segmented into two primary divisions: Innovative Medicines and Sandoz. The Innovative Medicines segment concentrates on delivering prescription medications to both patients and medical professionals. This division's extensive product portfolio addresses various therapeutic areas, including ophthalmology, neurological disorders, immunological conditions, liver diseases, dermatological ailments, respiratory illnesses, cardiovascular health, renal conditions, and metabolic imbalances. Conversely, the Sandoz division specializes in the development, manufacturing, and marketing of finished generic medications. It also supplies active pharmaceutical ingredients (APIs), including antibiotics and other intermediates, along with complete small-molecule pharmaceutical products to external companies. This segment's offerings further encompass retail generics, anti-infective treatments, and biotechnology-derived products such as biosimilars, in addition to providing specialized biotechnology manufacturing services. In terms of strategic alliances, Novartis AG maintains a licensing and collaborative agreement with Alnylam Pharmaceuticals for the development, production, and market introduction of inclisiran. Furthermore, the company is engaged in a clinical partnership with Kura Oncology, Inc., focused on evaluating the combined effectiveness of Tipifarnib and Alpelisib in individuals suffering from head and neck squamous cell carcinoma. Established in 1996, the corporation maintains its headquarters in Basel, Switzerland.
NOVN Stock 12 Month Forecast
Average Price Target
CHF125.70
▲(5.79% Upside)
Technical Analysis
Options Prices
Currently, No data available
---